EUVIMEDEUVIMED entdecken
Vergleichsstudie

Comparative disproportionality signals for methotrexate monotherapy versus methotrexate combined with hydroxychloroquine, leflunomide, or sulfasalazine in rheumatoid arthritis: newly highlighted signals evaluated using drug information safety profiles

Azfar Athar Ishaqui, Khalid Orayj, Zeeshan Ahmed, Salman Ashfaq Ahmad, Sultan M Alshahrani, Rayah Asiri, Adnan Iqbal, Asaad Ahmed Asaad Khalil, Mohammed Ali Kaddoura, Muhammad Bilal Maqsood

Naunyn-Schmiedeberg's Archives of Pharmacology · 2026

DOI: 10.1007/s00210-026-05100-7 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2026. Verfasst von Azfar Athar Ishaqui und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, College of Pharmacy, King Khalid University, Abha, Saudi Arabia. azfar.hd@hotmail.com. Hauptthemen laut MEDLINE: Sulfasalazine, Arthritis, Rheumatoid, Leflunomide, Methotrexate. Die Arbeit nennt 47 Literaturangaben. Gefördert von: Deanship of Scientific Research, King Khalid University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Methotrexate (MTX) is the anchor conventional synthetic disease-modifying antirheumatic drug (csDMARD) in rheumatoid arthritis. Postmarketing safety patterns may differ between MTX monotherapy and MTX-based dual-csDMARD combinations. This study aimed to compare disproportionality signals for MTX alone versus MTX combined with hydroxychloroquine, leflunomide, or sulfasalazine and comparison with drug information safety profiles. A retrospective disproportionality study was conducted using a spontaneous reporting database across 2016Q1 to 2025Q2. Groups were MTX only (MTX as primary suspect) and MTX + hydroxychloroquine, leflunomide, or sulfasalazine (two drug reports with one primary suspect and one secondary suspect). Reporting odds ratios (RORs) were estimated at system organ class (SOC) and preferred term (PT) levels. Significant PTs were checked against drug information safety profiles. Time-to-onset (TTO) was summarized. A total of 148,315 reports were eligible. SOC signals were modest for MTX only, and highest for infections and infestations (ROR = 1.77) and blood and lymphatic disorders (ROR = 1.77). Combination cohorts showed strong musculoskeletal signals (ROR 8.13 to 9.64) and investigations (ROR = 3.25 to 3.72). Selected PT RORs included mucosal inflammation = 12.47, bone marrow failure = 12.83, and B-cell lymphoma = 13.94 in MTX only. Chondropathy reached 19.16 in MTX + leflunomide. Lip blister reached 17.02 and compartment syndrome 17.56 in MTX + sulfasalazine. Early TTO was seen for vomiting (median 22 days; 67% within 30 days) and mucosal inflammation (median 14 days; 58% within 30 days) in MTX only. Drug ineffective was delayed across groups, up to 1422 days in MTX + hydroxychloroquine. Strict exposure signal detection identified regimen-specific SOC, PT, and TTO patterns. Several significant PTs were not captured in drug information profiles and warrant follow-up.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SulfasalazineArthritis, RheumatoidLeflunomideMethotrexateAntirheumatic AgentsHydroxychloroquineHumansFemaleRetrospective StudiesMaleDrug Therapy, CombinationMiddle AgedAgedDatabases, FactualAdultAdverse Drug Reaction Reporting Systems

Stichwörter der Autor:innen

Adverse effectsHydroxychloroquineLeflunomideMethotrexatePharmacovigilanceSulfasalazine

Substanzen

SulfasalazineLeflunomideMethotrexateAntirheumatic AgentsHydroxychloroquine

Autor:innen und Institutionen

  • Department of Clinical Pharmacy, College of Pharmacy, King Khalid University, Abha, Saudi Arabia. azfar.hd@hotmail.com.
  • Department of Clinical Pharmacy, College of Pharmacy, King Khalid University, Abha, Saudi Arabia.
  • Department of Pharmacy, Iqra University, Karachi, Pakistan.
  • Department of Pharmacology, Faculty of Pharmacy and Pharmaceutical Sciences, University of Karachi, Karachi, Pakistan.
  • Quality and Performance Administration, Eastern Health Cluster, Ministry of Health, Dammam, Saudi Arabia.
  • Clinical Excellence Administration, King Fahad Specialist Hospital, Dammam, Saudi Arabia.

Förderung

  • Deanship of Scientific Research, King Khalid University

Zitieren

APA

Ishaqui, A. A., Orayj, K., Ahmed, Z., Ahmad, S. A., Alshahrani, S. M., Asiri, R., Iqbal, A., Khalil, A. A. A., Kaddoura, M. A., & Maqsood, M. B. (2026). Comparative disproportionality signals for methotrexate monotherapy versus methotrexate combined with hydroxychloroquine, leflunomide, or sulfasalazine in rheumatoid arthritis: newly highlighted signals evaluated using drug information safety profiles. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-026-05100-7

Vancouver

Ishaqui AA, Orayj K, Ahmed Z, Ahmad SA, Alshahrani SM, Asiri R, et al. Comparative disproportionality signals for methotrexate monotherapy versus methotrexate combined with hydroxychloroquine, leflunomide, or sulfasalazine in rheumatoid arthritis: newly highlighted signals evaluated using drug information safety profiles. Naunyn-Schmiedeberg's Archives of Pharmacology. 2026. doi:10.1007/s00210-026-05100-7

BibTeX
@article{Ishaqui2026,
  author = {Ishaqui, Azfar Athar and Orayj, Khalid and Ahmed, Zeeshan and Ahmad, Salman Ashfaq and Alshahrani, Sultan M and Asiri, Rayah and Iqbal, Adnan and Khalil, Asaad Ahmed Asaad and Kaddoura, Mohammed Ali and Maqsood, Muhammad Bilal},
  title = {Comparative disproportionality signals for methotrexate monotherapy versus methotrexate combined with hydroxychloroquine, leflunomide, or sulfasalazine in rheumatoid arthritis: newly highlighted signals evaluated using drug information safety profiles},
  journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
  year = {2026},
  doi = {10.1007/s00210-026-05100-7}
}
Kostenlos starten →